Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these

Insiders' dealing


Report of transactions with shares and related securities of NeuroSearch by
persons discharging managerial responsibilities and persons/companies closely
associated with these 

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S (NEUR.CO) shall make public, transactions with shares and related
securities of NeuroSearch A/S by persons discharging managerial
responsibilities and persons/companies closely associated with these. 


Name: Anita Milland
Reason: Vice President, CFO
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 23 May 2008
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 79
Market value (DKK): 22,278


Contact person: 
Anita Milland, Vice President, CFO, telephone: +45 2016 3432




NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. The core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of NeuroSearch's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III), tesofensine in obesity (Phase III in
preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in
partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with
Astellas, ACR325 in bipolar disorder (Phase I), ABT-107 as well as ABT-560 for
the treatment of various CNS disorders - both (Phase I) in collaboration with
Abbott, NSD-644 in pain (Phase I) in partnership with GSK, ACR343 in
Parkinson's disease (Phase I) and NSD-788 in anxiety/depression (Phase I). In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.